The present invention relates to a process for in vitro spermatogenesis from male germinal tissue comprising conducting maturation of testicular tissue comprising germ cells in a bioreactor which is made of a bi-material and comprises at least one cavity wherein the germinal tissue is placed, and recovering elongated spermatids and/or spermatozoa.
The present invention relates to a process for implementing in vitro spermatogenesis and associated device.

Each year, 160,000 children worldwide are affected by pediatric cancer. Progress during the past 30 years in oncology, of which pediatric cancers were the major beneficiaries, can now achieve cure rates of 75-80% in developed countries. However, only 33% of male children who have survived cancer during childhood produce sperm of normal quality when they are adults. Indeed, cancer therapies are known for their gametotoxic effects that can cause sterility. While adults can be offered to freeze sperm before starting treatment (for example cancer therapy) to preserve their fertility, it is of course not possible for children. The only currently feasible conservation protocol for these boys is to make a collection and cryopreservation of their testicular tissue. However, today, there is no guarantee that future scientific advances will restore their fertility in the context of a medically assisted parental project.

There is thus a need to develop techniques to preserve the fertility of these children in order to fulfill their future parental project.

In addition to cancer therapies undergone during the childhood or adulthood, sterility can be due to genetical or acquired non-obstrusive azoospermia, bilateral chryptorchidism, severe sickle cell disease, etc.

There is thus a need to provide a process enabling to produce spermatozoa starting from testicular tissue in order to restore fertility.

For several decades, reproductive biologists have been trying to develop a technology to achieve spermatogenesis in vitro (ex vivo) in mammals. Spermatogenesis is a unique complex process involving several stages of cell division and cellular differentiation which leads to the formation of elongated spermatids and spermatozoa. A complete cycle of spermatogenesis takes about 30 days in mice, 54 days in rats and 72 days in human. Spermatogenesis occurs within the seminiferous tubules where the germ cells are in close association with Sertoli cells, the somatic cells needed to achieve this process. The local (intra-testicular) mechanisms regulating spermatogenesis still remain poorly understood. This partly explains why, despite sustained investment in research, no method has now reproduced in vitro (or ex vivo) this entire process in humans. The most significant advances in this field are recent. A Japanese team which has developed a method of organotypic culture has recently announced that they have obtained in vitro fertilizing sperm from spermatogonia of immature mice (Takuya Sato et al., Nature, 2011, 471, 504-508). While the identification of culture conditions that permit immature male germ cells to mature into functional sperm is a major breakthrough, there are still several issues that require attention. Not surprisingly, efficiency is a major concern. Only the peripheral region of testes fragments exhibited advanced spermatogenesis in their system, while the center lost normal morphology and had large numbers of degenerating cells after 40 days of culture. Far fewer elongated spermatids and spermatozoa are produced per input immature male germ cell using the currently available in vitro system than in a normal testis in vivo. Flagellated sperm were observed in only 5 out of 11 cultured explants from neonatal testes 2 and in only 3 out of 17 cultured explants from SSC transplanted testes (Sato et al., Nat Commun., 2011, 2, 472). More recently, a German-Israeli team used a co-culture of isolated testicular cells in 3D culture. However, they did not report on the ability of the spermatozoa obtained to produce offsprings. In addition, these techniques have drawbacks related to their implementation complexity and the large amount of biological tissue they require and seem hardly conductive to adaptation in humans.

Hollow fibers made of a coagulated polysaccharide hydrogel, such as based on chitosan, have been described and proposed as bioreactor that may be used in tissue engineering, biological membranes or slow-release vector. Hydrogels are 3D elastic networks with high water content, so that they can mimic hydrated native tissues. N.M.S. Bettahalli et al. (Acta Biomaterialia 7, 2011, 3312-3324) discloses the use of hollow fiber membranes to improve nutrient supply in three-dimensional tissue constructs in the field of tissue-engineered constructs based on scaffolds combined with cells or biological molecules for the treatment of tissue defects. Wang et al., Membr. Sci. 2000, 166, 31-39 disclose annular hollow fibers. WO2009/044053 discloses mono- or multilayered hollow fibers made of a coagulated polysaccharide hydrogel, such as based on chitosan. Robert E. Chapin and Kim Boekelheide (Reproductive Toxicology 39, 2013, 63-68) interested in the creation of in vitro models of tissues using human cells in the field of spermatogenesis and suggested that evaluation should be done of testis cells in some new hydrogels and/or 3D matrices that might support the development of multicompartments. They suggested that the presence of Sertoli cells and germ cells should be key to the in vitro reconstruction of the testis tissue.

There is still a need to provide a process to implement in vitro spermatogenesis for human and animals.

The objective of the present invention is to provide a process of in vitro spermatogenesis to obtain fertilizing elongated spermatids or spermatozoa which are fertilizing.

Another objective of the present invention is to provide such a process which is efficient even based on
Another objective of the present invention is to provide a process of in vitro fertilization. Other objectives will appear by reading the description below.

The above mentioned problems and prior art drawbacks are surprisingly solved by the present invention which relates to a process for in vitro (ex vivo) spermatogenesis from male germinal tissue comprising conducting maturation of said germinal tissue in a bioreactor which is made of a biomaterial and comprises at least one cavity wherein the germinal tissue is placed. At the end of the maturation process or a maturation time, elongated spermatids and/or spermatozoa are recovered.

The present invention is based on the finding that male germinal tissue is to be used and confined in a 3D biocompatible structure. The germinal tissue is a testicular tissue comprising germ cells. It is more preferably seminiferous tubules or fragment(s) of seminiferous tubules. It is generally more convenient to manipulate fragments of tubules, and it is advantageous to mix fragments of several different tubules in order to have cells (germ cells and/or Sertoli cells) at different stages. It may also be of interest to add to the tubules or fragments, germ cells or other seminiferous cells, recovered from seminiferous tubules or their fragments. The tubules are dissociated or separated from the remaining testicular tissue, in particular from the surrounding tissue or Leydig cells, for example by mechanical or chemical treatment.

The present invention thus relates to a process for in vitro spermatogenesis from male germinal tissue comprising conducting maturation of testicular tissue comprising germ cells in a bioreactor which is made of a biomaterial and comprises at least one cavity wherein the germinal tissue is placed, and recovering elongated spermatids and/or spermatozoa.

According to the invention, the testicular tissue comprises at least one seminiferous tubule or fragments of at least one seminiferous tubule, preferably several seminiferous tubules or fragments of several seminiferous tubules, more preferably fragments from 2, 3, 4, preferably 5, to 10, 20, 30, 40 or 50 seminiferous tubules (every combinations are encompassed). For example, the testicular tissue comprises fragments from 2 to 50, 3 to 40, 4 to 30, 5 to 20 seminiferous tubules. These tubules may come from testis from the same patient or donor, or from different donors.

The seminiferous tubules may be separated from the testis through methods known to the person skilled in the art. It may be a mechanical or enzymatic separation of the tubules with respect to the remaining testis and the Leydig cells, for example using collagenase and separation. It may be mechanical separation, for example using a scalpel and the like. "Fragments" means in the sense of the invention portions of the seminiferous tubules. The fragments of seminiferous tubules may have a size facilitating the manipulation thereof and their placing into the cavity. Typically, their size is comprised between about 1 and about 5 mm, this being the length of the fragments, as the original tubules, preferably comprise germ cells, Sertoli cells and peritubular cells (especially of myoid type), typically in or close to the native configuration within intact tubules. The testis may be from a patient or from one or several donors. In the process of the present invention, the germinal tissue is from a patient which can be a human or a non-human. Preferably, the patient is a human or a non-human mammal.

According to the invention, the testicular tissue comprises germ cells, Sertoli cells and peritubular cells. Leydig cells may also be present.

According to the invention, cells selected from the group consisting of germ cells, Sertoli cells, peritubular cells and mixtures thereof, are added to the testicular tissue.

Preferably, the germinal tissue can be either:

- a sample of the patient comprising seminiferous tubules, or fragments of seminiferous tubules, comprising germ cells; Sertoli cells; peritubular cells (especially of myoid type); and possibly Leydig cells; or
- seminiferous tubules or fragments of seminiferous tubules comprising germ cells obtained from the patient and admixed with at least Sertoli cells; peritubular cells (especially of myoid type); and possibly Leydig cells of one or more donors.

In addition to a) and b) it is also possible to add germ cells and/or Sertoli cells recovered from seminiferous tubules or their fragments, the tubules may have been dissociated for example by mechanical or chemical treatment and further treated to recover the germ cells and/or the Sertoli cells.

The male germinal tissue can be from a prepubertal or postpubertal patient. For example it can be from:

- A healthy prepubertal or postpubertal patient about to undergo a gonado-toxic treatment or surgery, for example cancer-therapy;
- A postpubertal patient having germinal tissue but who does not produce spermatozoa for example due to genetic or acquired non-obstructive azoospermia, bilateral chryptorchidism during childhood or severe sickle cell disease;
- A prepubertal patient having bilateral cryptorchidism or severe sickle cell disease;
- Endangered species;
- Horses, camel, dromedary or pets which will be submitted to a medical or surgical treatment, such as castration;
- livestock.

Preferably, the germinal tissue is from:

- A healthy prepubertal or postpubertal human or animal about to undergo a gonado-toxic treatment or surgery, for example cancer therapy;
- A postpubertal human or animal who does not produce spermatozoa for example due to genetic or acquired non-obstructive azoospermia, bilateral cryptorchidism during childhood or severe sickle cell disease;
- A prepubertal human having bilateral cryptorchidism or severe sickle cell disease.

[0024] The bioreactor of the present invention is made of a biomaterial and comprises at least one cavity wherein the germinal tissue is placed or confined. According to the present invention it should be understood by "a bioreactor comprises at least one cavity wherein the germinal tissue is placed or confined" that the bioreactor is either pre-constituted and comprises a cavity wherein the germinal tissue is introduced or the bioreactor is formed around the germinal tissue, the germinal tissue being thus comprised in a cavity which is formed around it during the formation of the bioreactor. Accordingly, it should be understood that the expression "place (or introduce or fill) the germinal tissue into at least one cavity of the bioreactor" means placing the germinal tissue into at least one cavity of a bioreactor or forming a bioreactor around the germinal tissue in order to confine it. Typically, the cavity is filled or substantially filled with the germinal tissue. Typically, the germinal tissue is confined or substantially confined in the cavity. Advantageously, the confinement will be maintained until the end of the maturation. If needed, fragments of biomaterial may be introduced into the channel along with the germinal tissue in order to help the confinement effect. According to a feature, the cavity is closed or sealed during the maturation process.

[0025] Advantageously, the germinal tissue is confined in the cavity which enables to maintain a 3-dimensional structure close to the in vivo structure of the seminiferous tubules. When seminiferous tubules or fragments thereof are used as germinal tissue (as mentioned below), the confinement allows to keep their structure along the maturation process. On the contrary, the actual devices for general cell maturation or the suggested methods based on isolated cells do not enable to match the in vivo architecture into seminiferous tubules and the cell maturation cannot be conducted until term.

[0026] The volume of the cavity is depending on the amount of germinal tissue that is used. Also, as explained herein, it is possible to add material, such as biomaterial, to help confinement inside the cavity. Typically, the volume of the cavity may go from about 1 to about 150 mm³, preferably from about 0.5 to about 30 mm³, for example from about 1 to about 5 mm³.

[0027] In an embodiment, the bioreactor comprises a pre-formed channel, it is for example a tubular bioreactor or a tube or hollow fiber made of a biomaterial, e.g. as known in the art. The diameter of the channel is thus suited to the amount and/or size of the germinal tissue in order that the germinal tissue can be placed and confined into the channel in accordance with the inventive concept. In other words, the volume of the channel is adapted to the quantity of germinal tissue introduced in order that the germinal tissue is confined in the channel. The skilled person is able to adapt the volume of the channel by modifying the diameter and/or the length of the channel. This diameter can be determined by the skilled person and is typically from about 100 µm to about 5 mm, preferably from about 1 mm to about 4 mm. Typically, the length of the bioreactor is from about 0.3 to about 5 cm, preferably from about 0.5 to about 3 cm. The germinal tissue is thus placed inside the channel.

[0028] In an embodiment, a hardening (e.g. coagulable, cross-linkable, reticulable, etc.) solution or material is placed around the germinal tissue and allowed to harden. The amount of material formed around the germinal tissue and its nature is suited to confine the germinal tissue, and the tissue confinement may be helped by an additional solid structure that may be used at the time of hardening or even it may be maintained to help keeping the structure during maturation (net, grid, walls, mold, container such as Petri dish, tube, ...).

[0029] Preferably and advantageously, the biomaterial is an hydrogel. Hydrogels are 3D elastic networks with high water content and they are able to mimic hydrated native tissues. According to the invention "hydrogel" means a viscoelastic mass comprising at least 80%, preferably at least 90% by weight of water, for example between 94 and 99% by weight of water, for example from 96 to 98.5% by weight of water. The hydrogel of the present invention is a chemical hydrogel (interactions responsible of the inter-chain cross-linking are of covalent bond type) or a physical hydrogel (interactions responsible of the inter-chain cross-linking are of physical type for example hydrogen bonds and/or hydrophobic interactions). Preferably, the hydrogel of the present invention is a physical hydrogel.

[0030] Preferably, the bioreactor is in a biomaterial having an effective permeability (porosity and/or diffusion) to the culture medium used for the maturation, to air and carbon dioxide. In one embodiment, the cavity is closed during the maturation process. For example, if a tube is used, extremities thereof are sealed. In another embodiment, the bioreactor is closed with a biomaterial permeable to the culture medium used for the maturation, to air and carbon dioxide, for example with a sheet of a biomaterial permeable to the culture medium used for the maturation, to air and carbon dioxide.

[0031] For example, the biomaterial comprises polysaccharides, preferably natural polysaccharides, including modified or hybrid polysaccharide, or collagen or a mixture thereof. "Comprises polysaccharides or collagen" means that the biomaterial may comprise at least one polysaccharide or collagen which is the raw compound at the basis of the hydrogel. The biomaterial will also contain ingredients required to produce the hydrogel, such as water, possible coagulant and the like, and other ingredients. It can be said that the biomaterial is or made of or based on the polysaccharide or the collagen.
Preferably, the biomaterial comprises a natural polysaccharide, especially chosen among chitosan, hyaluronic acids, alginites, pectines and modified natural polysaccharides such as carboxymethylcellulose (CMC), alone or in mixture. By way of example, the biomaterial comprises chitosan or alginites, alone or in mixture, e.g. chitosan.

Preferably, the biomaterial comprises chitosan or alginites, alone or in mixture, e.g. chitosan.

Preferably, the concentration of polysaccharide or collagen, e.g. chitosan, in the biomaterial, and preferably in the hydrogel, is from 1 to 20%, preferably from 1 to 6%, for example from 1.5 to 4 % by weight.

Preferably, the concentration of polysaccharide or collagen, e.g. chitosan, in the biomaterial, and preferably in the hydrogel, is from 1 to 20%, preferably from 1 to 6%, for example from 1.5 to 4 % by weight.

Advantageously, the biomaterial, and especially its surface structure, is such that it enables especially air, carbon dioxide, and the elements of the culture medium into which the bioreactor is placed for maturation, to diffuse through it, especially in order for air, carbon dioxide, and the elements of the culture medium to diffuse through it and reach the germinal tissue or the vicinity of the germinal tissue. Preferably, the thickness of the biomaterial around the cavity has to enable the diffusion of the different elements cited above and thus depend on the biomaterial. Preferably it is from about 0.1 to about 10 mm, preferably from about 0.1 to about 5 mm, preferably from about 0.5 to about 2 mm.

An example of suitable hollow fibers and method or preparation is described in WO2009044053. The person skilled in the art may refer to this document.

As mentioned herein, in the process according to the invention, the germinal tissue may be introduced into at least one channel or cavity of the bioreactor. Preferably, the channel is then closed at both ends or at the open end. For example, with a hollow fiber, a ligature may be done at both ends or at an open end or as mentioned above a permeable biomaterial can be used, preferably, a ligature may be done at both ends or at an open end.

Advantageously, the process of the present invention does not require large amounts of germinal tissue compared to the method previously implemented. Preferably, the amount of germinal tissue introduced into the bioreactor is from about 1 to about 150 mm³, preferably from about 0.5 to about 100 mm³, for example from about 1 to about 30 mm³. This is advantageous, because it is possible to produce elongated spermatids or spermatozoa from a reduced amount of germ cells. This renders the process useful for patients having very few germ cells.
prising the following steps:

a) Providing a sample of germinal tissue;
b) Providing a bioreactor which is made of a biomaterial and comprises at least one cavity according to the invention, and introducing said germinal tissue into the at least one cavity of said bioreactor; optionally sealing the bioreactor; or forming the bioreactor around the germinal tissue;
c) Placing said bioreactor containing said germinal tissue in a tank comprising a culture medium, especially as defined above;
d) Conducting maturation of the germinal tissue until elongated spermatids and/or spermatozoa are produced;
e) Recovering elongated spermatids and/or spermatozoa from the bioreactor.

[0049] Preferably, step f) is implemented as follow:
- opening of the bioreactor;
- micromanipulation to recover one or more spermatozoa and/or elongated spermatids.

[0050] Preferably, the invention relates to a process for in vitro (ex vivo) spermatogenesis comprising the following steps:

a) Providing a sample of germinal tissue;
b) Providing a bioreactor comprising at least one hollow fiber made of an hydrogel material, especially as a polysaccharide or collagen preferably in the physical hydrogel state; and
(c) Introducing the germinal tissue into the center channel of the hollow fiber; optionally sealing the hollow fiber;
d) Placing the hollow fiber containing the germinal tissue in a tank comprising a culture medium;
e) Conducting maturation of the germinal tissue until elongated spermatids and/or spermatozoa are produced;
f) Recovering elongated spermatids and/or spermatozoa from the hollow fiber.

[0051] In one embodiment, the bioreactor (or the hollow fiber) is immersed in the culture medium, a bubbling of air has to be implemented in order to have a sufficient oxygenation for the maturation.

[0052] In another embodiment, the bioreactor (or the hollow fiber) is placed at the interface between the air and the culture medium. This can be done by any method known by the skilled person and for example by adding in the tank comprising the culture medium a support at the interface between the air and said culture medium. This advantageously improves the oxygenation and consequently the maturation and the efficiency of the process according to the invention.

[0053] In one embodiment of the process of the invention, the culture medium comprises growth factors, hormones, vitamins, antibiotics metabolites, etc., alone or in mixture. For example the hormones can be chosen among insulin, testosterone, FSH (for example ovine/human FSH) alone or in mixture. For example the vitamins are chosen among vitamin C, vitamin E, vitamin A (retinoid acid, retinol), alone or in mixture. For example, the metabolites can be chosen among transferin, pyruvate, alone or in mixture.

[0054] In another embodiment, the culture medium comprises growth factors, hormones, vitamins, antibiotics metabolites, etc., alone or in mixture. For example the vitamins are chosen among vitamin C, vitamin E, vitamin A (retinoid acid, retinol), alone or in mixture. For example, the metabolites can be chosen among transferin, pyruvate, alone or in mixture. The testosterone is then added in the course of the process. Advantageously, at the end of a first wave of maturation, there is still round spermatids in the germinal tissue, and the process can be implemented at least one time more.

[0055] In one embodiment, the recovered elongated spermatids and/or spermatozoa are cryopreserved for future medically assisted parental project.

[0056] The germinal tissue in the process of the invention can be a fresh or cryopreserved germinal tissue fragment previously obtained from a patient.

[0057] The process of the present invention can also be understood as being a treatment for the infertility and/or as a process for preserving fertility. The process of the invention can also be understood as a process for medically assisted procreation.

[0058] The present invention also relates to a process of in vitro fertilization comprising the following steps:

a) Preparation of elongated spermatids and/or spermatozoids according to the process described above; or providing elongated spermatids and/or spermatozoa prepared using this process;
b) Fertilization of an oocyte with the elongated spermatids and/or spermatozoa from step a).

[0059] The present invention also relates to the use of a bioreactor made of a biomaterial and comprising at least one cavity for conducting in vitro spermatogenesis, preferably for the production of elongated spermatids and/or spermatozoa.

[0060] Preferably, the bioreactor is as defined above and is preferably a hollow fiber as described above.

[0061] The present invention also relates to a bioreactor made of a biomaterial and comprising at least one channel or cavity, as described above, and, within this cavity or channel, a germinal tissue as defined herein. As an example, the present invention relates to a hollow fiber comprising in its center channel a germinal tissue. The bioreactor may be an hydrogel, as defined herein.

[0062] The present invention also relates to a bioreac-
tor made of a biomaterial and comprising at least one channel or cavity, as described above, comprising in the channel or cavity elongated spermatids and/or spermatozoa. As an example, the invention also relates to hollow fiber, as described above, comprising in its center channel elongated spermatids and/or spermatozoa.

[0063] The present invention will now be described by means of examples.

Patients

[0064] The process according to the invention was implemented on 8 or 20 days-old male Sprague-Dawley rats. After anesthesia, animals were killed by decapitation, and their testes were quickly removed; the testes were immersed in Ham’s F-12/Dulbecco’s Modified Eagle’s medium (F12/DMEM, 1:1).

Preparation of Seminiferous Tubules

[0065] The tunica albuginea of testes was mechanically removed, and seminiferous tubules were isolated by digestion at 33°C in F12/DMEM (1:1) containing collagénase, 2 mg/ml lima bean trypsin inhibitor, and 10 mg/ml DNase for 10 min under gentle agitation. Seminiferous tubules were harvested by low-speed centrifugation, washed twice with F12/DMEM (1:1).

Preparation of the bioreactor:

[0066] The bioreactors are mono-membrane hollow fibers of chitosan obtained by the process described in WO2009044053. The bioreactor comprises 2% chitosan with acetylation degree of 4%, the interior of the channel has a volume of 20 to 50 mm³.

Spermatogenesis

[0067] 20 to 50 mm³ of the seminiferous tubules were introduced into chitosan tubes. The chitosan tubes were then sealed at both ends and then deposited in a conventional culture well containing approximately 8 ml of culture medium. The medium was changed every two days. The culture medium consisted of 15 mM Hapes-buffered F12/DMEM supplemented with antibiotics, 1.2 g/L NaHCO3, 10 µg/ml insulin, 10 µg/ml transferrin, 10⁻⁴ M vitamin C, 10 µg/ml vitamin E, 3.3 x 10⁻⁷ M retinoic acid, 3.3 x 10⁻⁷ M retinol, 10⁻³ M pyruvate (all from Sigma), 10⁻⁸M testosterone, and 50 ng/ml porcine FSH. For 8 days old rats the testosterone was added to the culture medium after several days of culture.

Histological studies

[0068] At selected days of culture, chitosan tubes and their cell contents were either fixed in Bouin’s fixative (Cold Spring Harbor Protocols) for 12-24 h and then embedded in paraffin; 4 µm thin sections were deparaffinized and rehydrated, or seminiferous tubules extruded from the chitosan tubes, were crushed between two microscopic glass slides. Then the nuclei were stained by Harris’s hematoxylin solution.

[0069] The results of the process implemented are presented in the figures.

Results on 20-days-old rats

[0070] In 20-days-old rats, at the beginning, the most differentiated germ cells are Pachytene spermatocytes (stage X).

[0071] At different days of culture, germ cells were observed. Cells had a similar appearance to their appearance in vivo. Round spermatids (step 1-4 of spermiogenesis) and elongated spermatids (step 9 of spermiogenesis) were visualized on day 11 of culture. After 39 days of culture a cluster of elongated spermatids with their flagella was observed (figure 1). It is also observed heads (A in figure 2) and flagella (B in figure 2) of elongated spermatids (ES) (step 15-17 of spermiogenesis) at a higher magnification.

[0072] A large cell mass was observed at day 39 (figures 7 and 8): early meiotic cells (Preleptotene and Leptotene spermatocytes) were still abundant and a new wave of round spermatids with young Pachytene spermatocytes was present.

Results on 8-days-old rats

[0073] By analogy with prepubertal boys who have only spermatogonia in their testes, semiferous tubule cultures from 8 days old rats were performed. Indeed, 8-days-old rats have only spermatogonia in their testes.

[0074] After 61 days of culture, cells are obtained after spreading the crushed cultured seminiferous tubules.

[0075] A cluster of elongated spermatids (C in figure 3) with their flagella in the lumen of the cultured seminiferous tubules were observed (figure 3). At a higher magnification, heads (D on figure 4) and flagella (E on figure 4) of ES were observed.

[0076] Figure 5 shows an isolated ES (step 19 of spermiogenesis). At a higher magnification (figure 6) it was observed the spermatid head (H), the cytoplasmic lobe (F) and the flagellum of the spermatid (G).

[0077] These results show that the process according to the invention enables to carry out spermatogenesis from a germinal tissue, i.e. from spermatogonia to spermatocytes or elongated spermatids.

Claims

1. Process for in vitro spermatogenesis from male germinal tissue comprising conducting maturation of testicular tissue comprising germ cells in a bioreactor which is made of a biomaterial and comprises at least one cavity wherein the germinal tissue is placed, and
recovering elongated spermatids and/or spermatozoa.

2. Process according to claim 1, wherein the testicular tissue comprises at least one seminiferous tubule or fragments of at least one seminiferous tubule, preferably several seminiferous tubules or fragments of several seminiferous tubules.

3. Process according to claim 2, wherein the testicular tissue comprises fragments from 2 to 50, 3 to 40, 4 to 30, 5 to 20 seminiferous tubules.

4. Process according to claim 2, wherein the tubules and/or fragments are obtained through mechanical separation or enzymatic separation of seminiferous tubules.

5. Process according to any one of claims 2 to 4, wherein the fragments of seminiferous tubules have a size comprised between about 1 mm and about 5 mm.

6. Process according to any one of claims 1 to 5, wherein the tubules and/or fragments are obtained through mechanical separation or enzymatic separation of seminiferous tubules.

7. Process according to any one of claims 1 to 6, wherein cells selected from the group consisting of germ cells, Sertoli cells, peritubular cells, and eventually Leydig cells, are added to the testicular tissue.

8. Process according to any one of claims 1 to 7, wherein the volume of the cavity or the volume of testicular tissue is from about 1 to about 100 mm³, preferably from about 0.5 to about 150 mm³, for example from about 1 to about 30 mm³.

9. Process according to anyone of claims 1 to 8, wherein the testicular tissue is from :
   - a healthy prepubertal or postpubertal patient about to undergo a gonado-toxic treatment or surgery, for example cancer-therapy;
   - a postpubertal patient who does not produce spermatozoa for example due to genetic or acquired non-obstructive azoospermia, bilateral cryptorchidism during childhood or severe sickle cell disease;
   - a prepubertal patient having bilateral cryptorchidism or severe sickle cell disease;
   - endangered species;
   - horses, camel, dromedary or pets;
   - livestock.

10. Process according to claim any one of the preceding claims, wherein the biomaterial is in the physical hydrogel state and preferably comprises a polysaccharide, preferably a natural polysaccharide, collagen or a mixture thereof.

11. Process according to claim 10, wherein the natural polysaccharide is chitosan, hyaluronic acid, alginate, pectine or a modified natural polysaccharide such as carboxymethylcellulose (CMC), alone or in mixture, preferably chitosan or alginate, alone or in mixture, preferably chitosan.

12. Process according to anyone of claims 1 to 11, comprising the following steps:
   a) Providing a sample of germinal tissue;
   b) Providing a bioreactor which is made of a biomaterial and comprises at least one cavity;
   c) Introducing said germinal tissue into the at least one cavity of said bioreactor, optionally sealing the bioreactor;
   d) Placing said bioreactor containing said germinal tissue in a tank comprising a culture medium;
   e) Conducting maturation of the germinal tissue until elongated spermatids and/or spermatozoa are obtained;
   f) Recovering elongated spermatids and/or spermatozoa from the bioreactor.

13. Process according to anyone of claims 1 to 12, wherein the bioreactor is formed around the germinal tissue.

14. Process according to anyone of claims 1 to 12, wherein the bioreactor is a hollow fiber of a biomaterial, comprising a channel wherein the germinal tissue is placed.

15. Process according to anyone of claims 1 to 14, wherein the bioreactor is made of an hydrogel.

16. Process according to anyone of claims 1 to 15, in which the bioreactor is placed in or at the contact of a culture medium, wherein :
   - the culture medium comprises one or more of growth factors, hormones, testosterone, vitamins, antibiotics, metabolites, etc., alone or in mixture; or
   - the culture medium comprises one or more of growth factors, hormones, vitamins, antibiotics metabolites, etc., alone or in mixture and testosterone is added to the culture medium in the course of the process.

17. Process according to anyone of claims 1 to 16, wherein the biomaterial is such that it enables air, carbon dioxide, and the elements of the culture medium into which the bioreactor is placed for matura-
tion, to diffuse through it.

18. Process of *in vitro* fertilization comprising the following steps:

a) Preparation of elongated spermatids and/or spermatozoa according to the process of anyone of claims 1 to 17; or providing elongated spermatids and/or spermatozoa by the process according to anyone of claims 1 to 17;

b) Fertilization of an oocyte with the elongated spermatids and/or spermatozoa obtained.
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of relevant passages</th>
<th>Relevant to claim</th>
<th>CLASSIFICATION OF THE APPLICATION (IPC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>SATO T ET AL: &quot;In vitro production of fertile sperm from murine spermatogonial stem cell lines&quot;. NATURE COMMUNICATIONS 2011 NATURE PUBLISHING GROUP GBR, vol. 2, no. 1, 2011, XP009176806, ISSN: 2041-1723 * abstract * * figure 1 *</td>
<td>1-18</td>
<td>C12N</td>
</tr>
</tbody>
</table>

The present search report has been drawn up for all claims.
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of relevant passages</th>
<th>Relevant to claim</th>
<th>CLASSIFICATION OF THE APPLICATION (IPC)</th>
</tr>
</thead>
</table>

The present search report has been drawn up for all claims.

Place of search: Munich  
Date of completion of the search: 12 March 2014  
Examiner: Loubradou-Bourges, N
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of relevant passages</th>
<th>Relevant to claim</th>
<th>CLASSIFICATION OF THE APPLICATION (IPC)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>* abstract *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* figure 5 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- pages 173-188, XP026809482, ISSN: 0012-1606 [retrieved on 2008-01-29]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* abstract *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* abstract *</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The present search report has been drawn up for all claims.
REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

• WO 2009044053 A [0008] [0036] [0066]

Non-patent literature cited in the description

• ROBERT E. CHAPIN; KIM BOEKELHEIDE. Reproductive Toxicology, 2013, vol. 39, 63-68 [0008]